Progress in diagnosis and treatment of gallbladder carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

YU Zhiyuan ,  SUN Yan

Department Seven of General Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin 150086, P. R. China;

Corresponding?author：

SUN Yan, Email: sunyandoctor@163.com

Keywords：

gallbladder carcinoma; progress in diagnosis; pathological stage; therapies

DOI：

10.7507/1007-9424.201812102

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To review the latest advances in diagnosis and treatment of gallbladder carcinoma.Methods The recent literatures on diagnosis and treatment of gallbladder carcinoma at home and abroad were reviewed, and the diagnosis, staging and treatment progress of gallbladder carcinoma were systematically reviewed.Results There are many methods to diagnose gallbladder carcinoma, among which imaging methods are commonly used, as well as various tumor markers and gallbladder carcinoma-related genes. Surgical resection is still the only possible cure for gallbladder carcinoma, but the scope and timing of surgical resection are still controversial. Radiotherapy, chemotherapy and gene therapy also play an important role in the treatment of gallbladder carcinoma.Conclusions Imaging examination is still the first choice for the diagnosis of gallbladder carcinoma. The tumor markers and gene diagnosis has broad prospects. Gallbladder carcinoma is mainly treated by surgery. Gene intervention and precise targeted therapy are the future development direction.

Citation： YU Zhiyuan, SUN Yan. Progress in diagnosis and treatment of gallbladder carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2019, 26(3): 282-287. doi: 10.7507/1007-9424.201812102 Copy

1.	吳森焱, 蔡軍. 膽囊癌診療現狀. 實用臨床醫學, 2016, 17(2): 102-107.
2.	Inui K, Yoshino J, Miyoshi H. Diagnosis of gallbladder tumors. Intern Med, 2011, 50(11): 1133-1136.
3.	Zhang HP, Bai M, Gu JY, et al. Value of contrast-enhanced ultrasound in the differential diagnosis of gallbladder lesion. World J Gastroenterol, 2018, 24(6): 744-751.
4.	Miwa H, Numata K, Sugimori K, et al. Differential diagnosis of gallbladder polypoid lesions using contrast-enhanced ultrasound. Abdom Radiol(NY), 2018 Nov 26.[Epub ahead of print].
5.	Ogura T, Kurisu Y, Masuda D, et al. Can endoscopic ultrasound-guided fine needle aspiration offer clinical benefit for thick-walled gallbladders? Dig Dis Sci, 2014, 59(8): 1917-1924.
6.	曾茂迪, 曾燕. 膽囊癌影像診斷研究進展. 現代醫藥衛生, 2018, 34(14): 2195-2198.
7.	林國福, 程莎莎, 梁健. CT和MRI對中晚期膽囊癌周圍臟器侵襲和轉移的診斷價值. 中國普外基礎與臨床雜志, 2012, 5(19): 562-564.
8.	陳藤, 吳宇. 超聲、MRI、CT在診斷原發性膽囊癌患者中應用. 中國CT和MRI雜志, 2015, 13(11): 66-69.
9.	劉雪松, 李鳳華. 膽囊癌影像學研究進展. 臨床超聲醫學雜志, 2014, 16(12): 830-833.
10.	吳平, 周克, 陳治明, 等. 18F氟代脫氧葡萄糖正電子發射斷層成像術/計算機斷層掃描顯像在膽囊癌中的診斷價值. 實用醫技雜志, 2014, 21(2): 131-135.
11.	汪嬌, 徐文貴, 戴東, 等. 18F-FDG PET/CT顯像在原發性膽囊癌診斷中的價值及優勢. 中國腫瘤臨床, 2013, 40(2): 103-106.
12.	Ke QH, He ZL, Duan X, et al. Chronic cholecystitis with hilar bile duct stricture mimicking gallbladder carcinoma on positron emission tomography: A case report. Mol Clin Oncol, 2013, 1(3): 517-520.
13.	Kumar R, Sharma P, Kumari A, et al. Role of 18F-FDG PET/CT in detecting recurrent gallbladder carcinoma. Clin Nucl Med, 2012, 37(5): 431-435.
14.	Puranik AD, Purandare N, Aqrawal A, et al. Bone marrow metastases in an otherwise operable gall bladder cancer: rare site of distant metastases detected on FDG PET/CT. Clin Nucl Med, 2014, 39(2): e169-e172.
15.	Sahoo MK, Sharma P, Suman S, et al. Gallbladder carcinoma metastasizing to adrenal gland: a rare site demonstrated with (18)F-FDG PET/CT. Clin Nucl Med, 2014, 39(2): 184-185.
16.	邱翔, 楊科, 趙玉婷, 等. PET/MRI在腫瘤研究中的新進展. 國際醫學放射學雜志, 2017, 40(1): 64-67.
17.	Liu F, Wang JK, Ma WJ, et al. Clinical value of preoperative CA19-9 levels in ebaluating resectability of gallbladder carcinoma. ANZ J Surg, 2018 Oct 10.[Epub ahead of print].
18.	龔平明, 姚成禮, 趙鑫. 血清CA199、CA125、CEA、CA153聯合檢測對膽囊癌的診斷價值. 山東醫藥, 2013, 53(23): 58-59.
19.	劉星雨, 范正軍. 高爾基體蛋白GP73和Ki-67在膽囊癌中的表達及臨床意義. 實用醫學雜志, 2017, 33(1): 47-50.
20.	Halder S, Kundu S, Chakraborty J, et al. Significance of HER2 and Ki-67 in preneoplastic lesions and carcinoma of gallbladder. J Gastrointest Cancer, 2018 Aug 29.[Epub ahead of print].
21.	張華洋. 膽囊癌生物學標志物研究進展. 中國普通外科雜志, 2014, 23(8): 1112-1116.
22.	Hsu M, Sasaki M, Igarashi S, et al. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. Cancer, 2013, 119(9): 1669-1674.
23.	陳義鋼, 顧琛. 轉移抑制基因1和微血管密度在膽囊癌中的表達及其臨床意義. 中國現代醫學雜志, 2017, 27(7): 46-49.
24.	孔煒偉, 陳駿, 何建, 等. 美國癌癥聯合委員會膽囊癌分期系統(第8版)更新的多學科解讀. 中國普外基礎與臨床雜志, 2017, 9(24): 1053-1056.
25.	湯朝暉, 田孝東, 魏妙艷, 等. 美國癌癥聯合委員會膽道惡性腫瘤分期系統(第8版)更新解讀. 中國實用外科雜志, 2017, 37(24): 248-254.
26.	Lee AJ, Chiang YJ, Lee JE, et al. Validation of American Joint Committee on Cancer eighth staging system for gallbladder cancer and its lymphadenectomy guidelines. Journal of Surgical Research, 2018, 230: 148-154.
27.	侯啟慧. 根治性切除術與腹腔鏡膽囊切除術治療早期膽囊癌患者的臨床效果對比. 中國民康醫學, 2017, 29(1): 31-32.
28.	諶利, 賈乾斌. 根治性膽囊切除術與腹腔鏡膽囊切除術治療早期膽囊癌患者的療效. 醫療設備, 2018, 31(9): 11-9120.
29.	陳亞進, 徐鋆耀. 腹腔鏡技術在膽囊癌根治術中的應用評價. 中國實用外科雜志, 2016, 36(10): 1040-1044.
30.	陳柏羽. 腹腔鏡膽囊切除術與根治性切除術治療膽囊癌的臨床效果觀察. 臨床合理用藥雜志, 2016, 9(29): 98-99.
31.	別平, 陳志宇. 膽囊癌診治的困惑及未來突破方向. 中國實用外科雜志, 2016, 36(10): 1021-1024.
32.	張鈴福, 候純升, 郭麗梅. 術中冰凍或術后石蠟病理報告T1b期膽囊癌的外科治療策略. 北京大學學報(醫學版), 2017, 49(06): 1034-1037.
33.	You DD, Lee HG, Paik KY, et al. What is an adequate extent of resection for T1 gallbladder cancers? Ann Surg, 2008, 247(5): 835-838.
34.	Benson AB 3rd, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw, 2009, 7(4): 350-391.
35.	王剛, 張龍輝, 張長坤, 朱繼業, 冷希圣, 王東. 不同手術方式治療早期膽囊癌的臨床療效比較. 中國普外基礎與臨床雜志, 2017, 24(10): 1220-1225.
36.	Dasari BVM, Ionescu MI, Pawlik TM, et al. Outcomes of surgical resection of gallbladder cancer in patients presenting with jaundice: A systematic review and meta-analysis. J Surg Oncol, 2018, 118(3): 477-485.
37.	Tatli F, Ozg?nül A, Yucel Y, et al. Incidental gallbladder cancer at cholecystectomy. Ann Ital Chir, 2017, 6: 399-402.
38.	Dincel O, Goksu M, Hatipoglu HS. Importance of routine histopathological examination of a gallbladder surgical specimen:Unexpected gallbladder cancer. J Cancer Res Ther, 2018, 14(6): 1325-1329.
39.	李春生, 鄒奇, 王勇. 腹腔鏡膽囊切除術意外膽囊癌21例臨床診治及預后分析. 肝膽胰外科雜志, 2015, 27(3): 241-243.
40.	張艷林, 張杰峰. 32例腹腔鏡膽囊切除術意外膽囊癌的臨床診治. 現代生物醫學進展, 2014, 14(7): 1320-1322, 1307.
41.	張亦馳, 王許安, 劉穎斌. 放射治療在膽囊癌綜合治療中的應用進展. 肝膽胰外科雜志, 2017, 29(5): 430-432, 436.
42.	水永杰, 魏啟春. 輔助放化療在膽囊綜合治療中的作用和地位. 中國實用外科雜志, 2016, 36(10): 1122-1124.
43.	Hakeem AR, Papoulas M, Menon KV. The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer-A systematic review. Eur J Surg Oncol, 2019, 45(2): 83-91.
44.	Dierks J, Gaspersz MP, Belkouz A, et al. Translating the ABC-02 trial daily practice:outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin. Acta Oncol, 2018, 57(6): 807-812.
45.	Wang N, Xiang X, Chen K, et al. Targeting of NT5E by miR-30b and miR-340 attenuates proliferation, invasion and migration of gallbladder carcinoma. Biochimie, 2018, 146: 56-67.
46.	Xue C, He Y, Hu Q, et al. Downregulation of P1M1 regulates glycolysis and suppresses tumor progression in gallbladder cancer. Cancer Manag Res, 2018, 10: 5101-5112.
47.	中國抗癌協會. 膽囊癌規范化診治專家共識(2016). 臨床肝膽病雜志, 2017, 33(4): 611-620.
48.	Aloia TA, Javle M, Maithel SK, et al. Gallbladder cancer: expert consensus statement. HPB (Oxford), 2015, 17(8): 681-690.
49.	Rajveer Hundal, Eldon A Shaffer. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol, 2014, 6: 99-109.
50.	耿金宏, 袁金鳳, 吳鳴, 等. 膽囊癌流行分布及高危因素探討研究. 臨床和實驗醫學雜志, 2012, 11(16): 1336-1337.

1. 吳森焱, 蔡軍. 膽囊癌診療現狀. 實用臨床醫學, 2016, 17(2): 102-107.
2. Inui K, Yoshino J, Miyoshi H. Diagnosis of gallbladder tumors. Intern Med, 2011, 50(11): 1133-1136.
3. Zhang HP, Bai M, Gu JY, et al. Value of contrast-enhanced ultrasound in the differential diagnosis of gallbladder lesion. World J Gastroenterol, 2018, 24(6): 744-751.
4. Miwa H, Numata K, Sugimori K, et al. Differential diagnosis of gallbladder polypoid lesions using contrast-enhanced ultrasound. Abdom Radiol(NY), 2018 Nov 26.[Epub ahead of print].
5. Ogura T, Kurisu Y, Masuda D, et al. Can endoscopic ultrasound-guided fine needle aspiration offer clinical benefit for thick-walled gallbladders? Dig Dis Sci, 2014, 59(8): 1917-1924.
6. 曾茂迪, 曾燕. 膽囊癌影像診斷研究進展. 現代醫藥衛生, 2018, 34(14): 2195-2198.
7. 林國福, 程莎莎, 梁健. CT和MRI對中晚期膽囊癌周圍臟器侵襲和轉移的診斷價值. 中國普外基礎與臨床雜志, 2012, 5(19): 562-564.
8. 陳藤, 吳宇. 超聲、MRI、CT在診斷原發性膽囊癌患者中應用. 中國CT和MRI雜志, 2015, 13(11): 66-69.
9. 劉雪松, 李鳳華. 膽囊癌影像學研究進展. 臨床超聲醫學雜志, 2014, 16(12): 830-833.
10. 吳平, 周克, 陳治明, 等. 18F氟代脫氧葡萄糖正電子發射斷層成像術/計算機斷層掃描顯像在膽囊癌中的診斷價值. 實用醫技雜志, 2014, 21(2): 131-135.
11. 汪嬌, 徐文貴, 戴東, 等. 18F-FDG PET/CT顯像在原發性膽囊癌診斷中的價值及優勢. 中國腫瘤臨床, 2013, 40(2): 103-106.
12. Ke QH, He ZL, Duan X, et al. Chronic cholecystitis with hilar bile duct stricture mimicking gallbladder carcinoma on positron emission tomography: A case report. Mol Clin Oncol, 2013, 1(3): 517-520.
13. Kumar R, Sharma P, Kumari A, et al. Role of 18F-FDG PET/CT in detecting recurrent gallbladder carcinoma. Clin Nucl Med, 2012, 37(5): 431-435.
14. Puranik AD, Purandare N, Aqrawal A, et al. Bone marrow metastases in an otherwise operable gall bladder cancer: rare site of distant metastases detected on FDG PET/CT. Clin Nucl Med, 2014, 39(2): e169-e172.
15. Sahoo MK, Sharma P, Suman S, et al. Gallbladder carcinoma metastasizing to adrenal gland: a rare site demonstrated with (18)F-FDG PET/CT. Clin Nucl Med, 2014, 39(2): 184-185.
16. 邱翔, 楊科, 趙玉婷, 等. PET/MRI在腫瘤研究中的新進展. 國際醫學放射學雜志, 2017, 40(1): 64-67.
17. Liu F, Wang JK, Ma WJ, et al. Clinical value of preoperative CA19-9 levels in ebaluating resectability of gallbladder carcinoma. ANZ J Surg, 2018 Oct 10.[Epub ahead of print].
18. 龔平明, 姚成禮, 趙鑫. 血清CA199、CA125、CEA、CA153聯合檢測對膽囊癌的診斷價值. 山東醫藥, 2013, 53(23): 58-59.
19. 劉星雨, 范正軍. 高爾基體蛋白GP73和Ki-67在膽囊癌中的表達及臨床意義. 實用醫學雜志, 2017, 33(1): 47-50.
20. Halder S, Kundu S, Chakraborty J, et al. Significance of HER2 and Ki-67 in preneoplastic lesions and carcinoma of gallbladder. J Gastrointest Cancer, 2018 Aug 29.[Epub ahead of print].
21. 張華洋. 膽囊癌生物學標志物研究進展. 中國普通外科雜志, 2014, 23(8): 1112-1116.
22. Hsu M, Sasaki M, Igarashi S, et al. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. Cancer, 2013, 119(9): 1669-1674.
23. 陳義鋼, 顧琛. 轉移抑制基因1和微血管密度在膽囊癌中的表達及其臨床意義. 中國現代醫學雜志, 2017, 27(7): 46-49.
24. 孔煒偉, 陳駿, 何建, 等. 美國癌癥聯合委員會膽囊癌分期系統(第8版)更新的多學科解讀. 中國普外基礎與臨床雜志, 2017, 9(24): 1053-1056.
25. 湯朝暉, 田孝東, 魏妙艷, 等. 美國癌癥聯合委員會膽道惡性腫瘤分期系統(第8版)更新解讀. 中國實用外科雜志, 2017, 37(24): 248-254.
26. Lee AJ, Chiang YJ, Lee JE, et al. Validation of American Joint Committee on Cancer eighth staging system for gallbladder cancer and its lymphadenectomy guidelines. Journal of Surgical Research, 2018, 230: 148-154.
27. 侯啟慧. 根治性切除術與腹腔鏡膽囊切除術治療早期膽囊癌患者的臨床效果對比. 中國民康醫學, 2017, 29(1): 31-32.
28. 諶利, 賈乾斌. 根治性膽囊切除術與腹腔鏡膽囊切除術治療早期膽囊癌患者的療效. 醫療設備, 2018, 31(9): 11-9120.
29. 陳亞進, 徐鋆耀. 腹腔鏡技術在膽囊癌根治術中的應用評價. 中國實用外科雜志, 2016, 36(10): 1040-1044.
30. 陳柏羽. 腹腔鏡膽囊切除術與根治性切除術治療膽囊癌的臨床效果觀察. 臨床合理用藥雜志, 2016, 9(29): 98-99.
31. 別平, 陳志宇. 膽囊癌診治的困惑及未來突破方向. 中國實用外科雜志, 2016, 36(10): 1021-1024.
32. 張鈴福, 候純升, 郭麗梅. 術中冰凍或術后石蠟病理報告T1b期膽囊癌的外科治療策略. 北京大學學報(醫學版), 2017, 49(06): 1034-1037.
33. You DD, Lee HG, Paik KY, et al. What is an adequate extent of resection for T1 gallbladder cancers? Ann Surg, 2008, 247(5): 835-838.
34. Benson AB 3rd, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw, 2009, 7(4): 350-391.
35. 王剛, 張龍輝, 張長坤, 朱繼業, 冷希圣, 王東. 不同手術方式治療早期膽囊癌的臨床療效比較. 中國普外基礎與臨床雜志, 2017, 24(10): 1220-1225.
36. Dasari BVM, Ionescu MI, Pawlik TM, et al. Outcomes of surgical resection of gallbladder cancer in patients presenting with jaundice: A systematic review and meta-analysis. J Surg Oncol, 2018, 118(3): 477-485.
37. Tatli F, Ozg?nül A, Yucel Y, et al. Incidental gallbladder cancer at cholecystectomy. Ann Ital Chir, 2017, 6: 399-402.
38. Dincel O, Goksu M, Hatipoglu HS. Importance of routine histopathological examination of a gallbladder surgical specimen:Unexpected gallbladder cancer. J Cancer Res Ther, 2018, 14(6): 1325-1329.
39. 李春生, 鄒奇, 王勇. 腹腔鏡膽囊切除術意外膽囊癌21例臨床診治及預后分析. 肝膽胰外科雜志, 2015, 27(3): 241-243.
40. 張艷林, 張杰峰. 32例腹腔鏡膽囊切除術意外膽囊癌的臨床診治. 現代生物醫學進展, 2014, 14(7): 1320-1322, 1307.
41. 張亦馳, 王許安, 劉穎斌. 放射治療在膽囊癌綜合治療中的應用進展. 肝膽胰外科雜志, 2017, 29(5): 430-432, 436.
42. 水永杰, 魏啟春. 輔助放化療在膽囊綜合治療中的作用和地位. 中國實用外科雜志, 2016, 36(10): 1122-1124.
43. Hakeem AR, Papoulas M, Menon KV. The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer-A systematic review. Eur J Surg Oncol, 2019, 45(2): 83-91.
44. Dierks J, Gaspersz MP, Belkouz A, et al. Translating the ABC-02 trial daily practice:outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin. Acta Oncol, 2018, 57(6): 807-812.
45. Wang N, Xiang X, Chen K, et al. Targeting of NT5E by miR-30b and miR-340 attenuates proliferation, invasion and migration of gallbladder carcinoma. Biochimie, 2018, 146: 56-67.
46. Xue C, He Y, Hu Q, et al. Downregulation of P1M1 regulates glycolysis and suppresses tumor progression in gallbladder cancer. Cancer Manag Res, 2018, 10: 5101-5112.
47. 中國抗癌協會. 膽囊癌規范化診治專家共識(2016). 臨床肝膽病雜志, 2017, 33(4): 611-620.
48. Aloia TA, Javle M, Maithel SK, et al. Gallbladder cancer: expert consensus statement. HPB (Oxford), 2015, 17(8): 681-690.
49. Rajveer Hundal, Eldon A Shaffer. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol, 2014, 6: 99-109.
50. 耿金宏, 袁金鳳, 吳鳴, 等. 膽囊癌流行分布及高危因素探討研究. 臨床和實驗醫學雜志, 2012, 11(16): 1336-1337.

Previous Article
Research advances in lymph node dissection in non-small cell lung cancer
Next Article
Research advances in lymph node dissection in non-small cell lung cancer

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Progress in diagnosis and treatment of gallbladder carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content